IL13RA2 and primary cutaneous T-cell non-Hodgkin lymphoma: However, dupilumab has also been associated with the “unmasking” of undiagnosed cutaneous T-cell lymphomas, driven by increased IL-13Rα2 signaling activating tumor proliferation and immune evasion, resulting in generalized lymphadenopathy and B-symptoms after initiation of dupilumab.10